Finally, histopathological analysis of samples from patients with HNSCC revealed that high caveolin-1 and low Sox-2 was predictive of clinical response to cetuximab, whereas low caveolin-1 and high Sox-2 was predictive of intrinsic cetuximab resistance. This evidence concerns the gene CAV1 and head and neck squamous cell carcinoma.